AI assistant
VOLITIONRX LTD — Director's Dealing 2022
Apr 8, 2022
34395_dirs_2022-04-08_4fe5b68f-79b7-4211-81fe-4afb32958aca.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: VOLITIONRX LTD (VNRX)
CIK: 0000093314
Period of Report: 2022-04-07-05:00
Reporting Person: Reynolds Cameron John (N/A)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2022-04-07-05:00 | Common Stock | A | 17375 | — | Acquired | 1159748 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2022-04-07-05:00 | Stock Option (Right to Buy) | $3.40 | A | 32020 | Acquired | 2031-08-03-05:00 | Common Stock (32020) | Direct |
Holdings (Non-Derivative)
| Security | Shares | Ownership |
|---|---|---|
| Common Stock | 1007718 | Indirect |
| Common Stock | 34076 | Indirect |
Footnotes
F1: On August 3, 2021, the reporting person was awarded 49,645 restricted stock units, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 17,375 restricted stock units vesting. The restricted stock units are further subject to a 2-year time-based vesting schedule, vesting in two installments of 8,687 units and 8,688 units on each of August 3, 2022 and August 3, 2023, respectively. Upon vesting and settlement, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.
F2: The shares of Common Stock are held directly by Concord International, Inc. Mr. Reynolds is the majority shareholder of Concord International, Inc. and shares voting and dispositive control over the shares of Common Stock held by Concord International, Inc.
F3: On August 3, 2021, the reporting person was granted an option to purchase 91,486 shares of common stock, subject to vesting upon achievement of certain corporate performance goals on or prior to July 1, 2022 and also subject to time-based vesting. Certain of the performance goals were met, resulting in the rights with respect to 32,020 shares vesting. The vested shares are further subject to a 2-year time based vesting schedule, vesting in two equal installments of 16,010 shares on each of August 3, 2022 and August 3, 2023, respectively.